195 related articles for article (PubMed ID: 15538746)
1. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Thomas LN; Lazier CB; Gupta R; Norman RW; Troyer DA; O'Brien SP; Rittmaster RS
Prostate; 2005 May; 63(3):231-9. PubMed ID: 15538746
[TBL] [Abstract][Full Text] [Related]
2. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
[TBL] [Abstract][Full Text] [Related]
3. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
[TBL] [Abstract][Full Text] [Related]
4. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
[TBL] [Abstract][Full Text] [Related]
5. 5alpha-reductase isoenzymes 1 and 2 in the rat testis during postnatal development.
Killian J; Pratis K; Clifton RJ; Stanton PG; Robertson DM; O'Donnell L
Biol Reprod; 2003 May; 68(5):1711-8. PubMed ID: 12606426
[TBL] [Abstract][Full Text] [Related]
6. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
Thomas LN; Douglas RC; Lazier CB; Gupta R; Norman RW; Murphy PR; Rittmaster RS; Too CK
J Urol; 2008 Jan; 179(1):147-51. PubMed ID: 17997435
[TBL] [Abstract][Full Text] [Related]
7. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.
Titus MA; Gregory CW; Ford OH; Schell MJ; Maygarden SJ; Mohler JL
Clin Cancer Res; 2005 Jun; 11(12):4365-71. PubMed ID: 15958619
[TBL] [Abstract][Full Text] [Related]
8. Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status.
Torres JM; Ruiz E; Ortega E
Prostate; 2003 Jun; 56(1):74-9. PubMed ID: 12746849
[TBL] [Abstract][Full Text] [Related]
9. Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.
Festuccia C; Angelucci A; Gravina GL; Muzi P; Vicentini C; Bologna M
J Cancer Res Clin Oncol; 2005 Apr; 131(4):243-54. PubMed ID: 15650886
[TBL] [Abstract][Full Text] [Related]
10. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M
Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of 5 alpha-reductase type 1 increases sensitivity of prostate cancer cells to low concentrations of testosterone.
Thomas LN; Douglas RC; Rittmaster RS; Too CK
Prostate; 2009 May; 69(6):595-602. PubMed ID: 19125422
[TBL] [Abstract][Full Text] [Related]
12. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
[TBL] [Abstract][Full Text] [Related]
13. [Expression and significance of steroid 5alpha-reductase isoenzymes in benign hyperplastic prostate tissues].
Ye LF; Zhang YF; Fang ZJ; Ding Q; Yao MS
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1296-9. PubMed ID: 12930680
[TBL] [Abstract][Full Text] [Related]
14. The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
Habib FK; Ross M; Bayne CW; Bollina P; Grigor K; Chapman K
Clin Cancer Res; 2003 May; 9(5):1815-9. PubMed ID: 12738739
[TBL] [Abstract][Full Text] [Related]
15. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
16. 5alpha-reductase isozymes and androgen actions in the prostate.
Zhu YS; Imperato-McGinley JL
Ann N Y Acad Sci; 2009 Feb; 1155():43-56. PubMed ID: 19250191
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
Bjartell A; Johansson R; Björk T; Gadaleanu V; Lundwall A; Lilja H; Kjeldsen L; Udby L
Prostate; 2006 May; 66(6):591-603. PubMed ID: 16388501
[TBL] [Abstract][Full Text] [Related]
18. Biology and natural history of prostate cancer and the role of chemoprevention.
Rosenberg MT; Froehner M; Albala D; Miner MM
Int J Clin Pract; 2010 Dec; 64(13):1746-53. PubMed ID: 21070525
[TBL] [Abstract][Full Text] [Related]
19. Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue.
Shirakawa T; Okada H; Acharya B; Zhang Z; Hinata N; Wada Y; Uji T; Kamidono S; Gotoh A
Prostate; 2004 Jan; 58(1):33-40. PubMed ID: 14673950
[TBL] [Abstract][Full Text] [Related]
20. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA.
Banerjee AG; Liu J; Yuan Y; Gopalakrishnan VK; Johansson SL; Dinda AK; Gupta NP; Trevino L; Vishwanatha JK
Mol Cancer; 2003 Oct; 2():34. PubMed ID: 14613585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
